Avis Co., Ltd. (CEO Daehong Lee), a medical artificial intelligence (AI) specialized company, announced on the 9th that its thyroid cancer diagnosis pathology AI solution 'PathoAiD®-Thyroid Dx' won a silver award at the '2025 Edison Awards' held in Fort Myers, Florida, USA, raising its status in the global medical technology market.
This Edison Award-winning product was developed to resolve the uncertainty and misdiagnosis problems that may arise during the pathological diagnosis of thyroid nodules. Compared to traditional diagnostic methods, it is expected to significantly reduce unnecessary surgeries and patient burden that were commonly seen in the past by having AI directly analyze thyroid nodule tissue slide images to quickly and accurately determine benign and malignant. In addition, it can reduce costs by up to 80% compared to expensive molecular tests, and maximize patient convenience by shortening the analysis period of more than 4 weeks required for the existing diagnostic process to just a few minutes, proving its technological excellence as well as its economic and social effects.
The Edison Awards is a prestigious event that honors the achievements of world-renowned inventor Thomas Edison and comprehensively evaluates innovation, technical excellence, marketability, and social influence. Avis' 'Pasoade' met these evaluation criteria and received high praise from the judges.
In addition, Avis presented two research results related to the core AI technology of this award-winning product at the '2025 American and Canadian College of Pathologists (USCAP 2025)' held at the Boston Convention Center from March 22 to 27. The presentation confirmed the clinical usability of the heat map generated by AI by showing a high degree of consistency with the actual pathologist's reading area, suggesting that both the technology and research results are recognized internationally.
Avis CEO Lee Dae-hong said, “The Edison Award is a global award that simultaneously evaluates innovative technology and social value. Through this award, the competitiveness of Avis’ thyroid cancer diagnosis AI solution has been recognized on the global stage.” He added, “We will continue to do our best to lead AI-based innovation in the field of precision medicine and actively promote the excellence of Korean medical technology to the global pathology community.”
With this award as an opportunity, Avis plans to utilize various opportunities such as global medical networking and investment attraction to more actively advance into overseas markets, and also spur technological innovation for the continuous development of the precision medicine field.
- See more related articles
You must be logged in to post a comment.